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Abstract
We reappraised the five randomized controlled trials that compared cardioto-
cography plus ECG ST interval analysis (CTG+ST) vs. cardiotocography. The
numbers enrolled ranged from 5681 (Dutch randomized controlled trial) to
799 (French randomized controlled trial). The Swedish randomized controlled
trial (n = 5049) was the only trial adequately powered to show a difference in
metabolic acidosis, and the Plymouth randomized controlled trial (n = 2434)
was only powered to show a difference in operative delivery for fetal distress.
There were considerable differences in study design: the French randomized
controlled trial used different inclusion criteria, and the Finnish randomized
controlled trial (n = 1483) used a different metabolic acidosis definition. In the
CTG+ST study arms, the larger Plymouth, Swedish and Dutch trials showed
lower operative delivery and metabolic acidosis rates, whereas the smaller Finn-
ish and French trials showed minor differences in operative delivery and higher
metabolic acidosis rates. We conclude that the differences in outcomes are
likely due to the considerable differences in study design and size. This will
enhance heterogeneity effects in any subsequent meta-analysis.
Abbreviations: BD, base deficit; BDblood, base deficit in blood; BDecf, base
deficit in extracellular fluid; CI, confidence interval; CTG, cardiotocography;
FBS, fetal scalp blood sampling; ITT, intention-to-treat; MA, meta-analysis;
NICU, neonatal intensive care unit; ODFD, operative delivery for fetal distress;
OR, odds ratio; RCT, randomized controlled trial; RR, risk ratio.
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Introduction
From 2012 to 2013, five independent meta-analyses
(MAs) of the value of intrapartum fetal surveillance with
cardiotocography (CTG) plus ST interval analysis
(CTG+ST) of the electrocardiogram compared with CTG
alone were published (1–5). In the same time frame,
international clinical experience with the CTG+ST analy-
sis method increased, as noted in numerous observational
studies (6–11). With the current attention focused on the
CTG+ST fetal surveillance method, we believe that a thor-
ough review of the quality of the original five randomized
controlled trials (RCTs) (12–16) was warranted, as well as
a critical review of the quality of the five MAs that have
followed (1–5). This article addresses the quality of the
RCTs, while a companion piece will focus on the MAs.
Five randomized controlled trials
Our review addressed the following issues in the RCTs:
(i) power calculations; (ii) pre-study training, inclusion
criteria, randomization and recruitment pace; (iii) intra-
partum management protocols; (iv) intrapartum interven-
tions; (v) cord blood and early neonatal metabolic
acidosis; (vi) neonatal outcomes. For supplementary sta-
tistical calculations, we used the MEDCALC version
5.00.017 computer software (MedCalc Software, Mari-
akerke, Belgium). Two-sided statistics were performed
with a p-value <0.05 considered significant.
The first RCT on CTG+ST analysis vs. CTG alone, the
Plymouth trial, was published in 1993 (12), followed by
the Swedish trial in 2001 (13), the Finnish trial in 2006
(14), the French trial in 2007 (15), and the Dutch trial in
2010 (16). After receiving criticism about quality control,
revised data from the Swedish and Dutch RCTs were
published in 2011 (17–19). Metabolic acidosis data from
the Finnish RCT have been revised (see below), but data
from the Plymouth and French RCTs have not been
revised.
Power calculations of outcome variables
Neonatal metabolic acidosis was the primary outcome
variable in the Plymouth, Swedish and Dutch RCTs but
not in the Finnish and French RCTs. Table 1 shows that
neither the Finnish nor French RCTs were adequately
powered to address this outcome. Due to a 46.5 and 73%
lower than expected incidence of metabolic acidosis in
the Plymouth and the Dutch RCTs, respectively, these tri-
als were also found to be underpowered for this outcome
(Table 1). Therefore, the majority of the RCTs failed to
attain their recruitment goals and/or were underpowered
for their primary outcome. Estimation of the incidences
of the primary endpoints was accurate in the control
group (i.e. in the CTG-alone group) only in the Swedish
RCT (metabolic acidosis) and in the Plymouth RCT
(operative delivery for fetal distress, ODFD).
Pre-trial training, inclusion criteria,
randomization and recruitment pace
While all RCTs offered some form of pre-trial training
(Table 2), the Plymouth RCT included a 100-case test
period before enrollment. The Swedish RCT required a 2-
month practice period before enrollment started and
there was re-training during the trial. The Dutch RCT
required certification and a 2-month practice period
before enrollment started. It therefore seems that these
three RCTs dealt more carefully with the potential prob-
lem of staff proficiency in applying the ST analysis meth-
odology to clinical care, thereby increasing the likelihood
of its proper use.
An interim analysis or safety committee watch was per-
formed in all but the Finnish and French RCTs (Table 2).
The inclusion criteria differed among the RCTs. The most
important difference was noted in the French RCT, as the
investigators recruited only cases considered to have sus-
picious or pathological CTGs (86% of enrollees) or thick
meconium-stained amniotic fluid (7%), or both (7%) at
the start-up of monitoring. Cases with a normal CTG
and no decelerations were excluded. However, the inclu-
sion of patients with a pathological CTG at start-up of
ST analysis violated the CTG+ST analysis clinical guide-
lines (20). To enable establishment of a fetal electro-
cardiogram T/QRS ratio baseline, ST monitoring should
be initiated while the fetus is still well oxygenated and the
CTG is not pathological. The French RCT data included
in the MA by Schuit et al. (5) indicate that in several
cases deterioration of the fetal condition might have
already occurred before enrollment. The basis for this
requirement is that alerts for changes in the ST interval,
signaling fetal hypoxia and impending metabolic acidosis,
may not occur if the fetal condition has already deterio-
rated and myocardial reserve is exhausted. Consequently,
the prerequisites for use of the CTG+ST analysis method
were not fulfilled in many cases in the French RCT.
Key Message
Among the randomized controlled trials, the Plym-
outh, Swedish and Dutch trials have the most similar
design and therefore should be the main source of
information regarding the effectiveness of CTG+ST
analysis for fetal surveillance in labor.
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Table 2. Study performance.
Trial Plymouth RCT Swedish RCT Finnish RCT French RCT Dutch RCT
Pre-study
training
Yes, with 100 cases Yes, during 2 months,
certification of users
Yes, but time not
reported
Yes, but time not
reported
Yes, at least 2 months,
certification of users
Interim
analysis
Yes, after 1200
included cases
Yes, after 1600
included cases
No information Not planned Serious events
monitored by Safety
Committee
Inclusion
criteria
>34 weeks, high-risk
with indication for
continuous CTG,
breech included
≥36 weeks, scalp
electrode decided
because of
increased risk
≥36 weeks,
amniotomy decided
≥36 weeks, suspicious
or pathological
CTG, thick
meconium
≥36 weeks, high-risk
needing CTG
monitoring,
abnormal/
nonreassuring CTG
accepted after
normal FBS
Exclusion
criteria
Gross fetal
abnormality
Multiple pregnancy,
non-cephalic, no
indication for scalp
electrode
Scalp electrode
contraindicated,
multiple pregnancy,
non-cephalic
presentation,
start-up in second
stage of labor
Multiple pregnancy,
non-cephalic,
cardiac malformation,
contraindication
scalp electrode,
normal CTG with no
decelerations,
severely abnormal
CTG at arrival
<18 years, multiple,
non-cephalic, no
indication for scalp
electrode
CTG-only group
monitoring
(internal/
external)
Conventional fetal
heart rate monitors,
internal monitoring
STAN S21 prototypes
(ST data blinded),
internal monitoring
Conventional fetal
heart rate monitors,
internal or external
monitoring
Conventional fetal
heart rate monitors,
internal or external
monitoring not
specified
Conventional fetal
heart rate monitors,
internal monitoring
Randomization Sealed envelopes Allocation by STAN
monitor at start-up
Sealed envelopes Sealed envelopes Web-based computer
program, stratified
for center and
parity
No. randomized Data cannot be
extracted from
article
5049 1483 Data cannot be
extracted from
article
5681
No. in ITT
analysis
2434 4966 (original data)
5049 (revised data)
1472 (1436 neonatal
outcome, exclusions
due to missing cord
blood gas data)
799 5667
Type of ITT Modified (only cases
with full cord blood
gas panel included?)
Standardized for
metabolic acidosis
(all randomized
cases included)
and modified
(non-eligible cases
excluded)
Modified (exclusions:
protocol violations,
missing patient
records, study
withdrawals;
neonatal outcome:
only cases with full
cord blood gas
data)
Modified (only cases
with full cord blood
gas panel included?)
Modified
(14 non-eligible
cases excluded,
representing 0.25%
of the series)
Number of
centers
1 3 1 2 9
Months of study 18 18 14 27 30
Recruitments
per center
and month
135 94 106 15 21
Percent of total
population
included in
study
36% 33% 33% 8% Data cannot be
extracted from
article
CTG, cardiotocography; FBS, fetal scalp blood sampling for determination of pH; ITT, intention-to-treat; RCT, randomized controlled trials.
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In the Plymouth, Swedish and Dutch RCTs, cases at
increased risk of fetal hypoxia in labor were recruited
(Table 2). Inclusion of cases with a nonreassuring fetal
heart rate was also allowed in these RCTs, but the major-
ity of cases recruited in the French RCT were at consider-
ably higher risk. This is illustrated by the crude French
RCT data presented in the MA by Schuit et al. (5), where
a composite adverse outcome was two to four times more
common in the French RCT than in the other RCTs. In
the Finnish RCT recruitment was made consecutively
after amniotomy. It is unclear whether amniotomy was a
routine procedure for active management of labor or per-
formed for specific indications.
The monitoring techniques in the CTG arm of the
RCTs varied (Table 2). Only the Swedish RCT used
STAN S21 monitors (Neoventa Medical AB, G€oteborg,
Sweden) for both study groups, while the other RCTs
used different monitoring systems, allowed external CTG
recording or did not specify the methodology used in the
control groups. In general, external fetal heart rate moni-
toring provides inferior CTG signal quality when com-
pared with internal signals (21). This might have
introduced bias in the CTG-only group in the RCTs that
allowed this modality.
Robust methods for allocation of women were used in all
five RCTs but standardized intention-to-treat (ITT) analy-
ses, including patients later excluded for various reasons,
were not generally available (Table 2). A revised report of
the Swedish RCT that included all randomized cases (17)
was the only effort to address this issue. However, the
Dutch RCT excluded only 14 cases (0.25%) from the ITT.
Leip€al€a et al. (22) requested an explanation of why the
Swedish trial was revisited. The original Swedish RCT
(13) was reported as a per-protocol analysis and by modi-
fied ITT analysis, i.e. including only the 4966 eligible
cases. After criticism for not including all randomized
cases and for misclassification of cases, a so-called stan-
dardized ITT on the primary outcome parameter meta-
bolic acidosis was performed (17). In the standardized
ITT analysis (n = 5049), 83 allocated cases that did not
fulfill the inclusion criteria were added. These were cases
of delivery before 36 weeks of gestation, breech delivery,
malformations, and cases included after the trial was
closed (23). Furthermore, the standardized ITT analysis
was extended to include not only validated umbilical cord
blood samples, but all cord blood determinations per-
formed, neonatal blood tests showing metabolic acidosis,
and imputed data in cases with missing acid–base data.
Table 2 also indicates that there were considerable vari-
ations in duration, enrollment pace and inclusion criteria
among trials. The Plymouth, Swedish and Finnish RCTs
ran for a period of 18 months or less with 94–
135 enrollments/center/month, whereas the French and
Dutch RCTs took 2 and 2½ years to complete, respec-
tively, with an enrollment pace of 15–21 patients/center/
month. However, the Dutch RCT adjusted statistically for
the stratified randomization by center (and parity). Less
frequent use of the ST analysis methodology may have
contributed to a slower gain in staff experience, so influ-
encing clinical decisions and possibly affecting the study
results. Differences in population sample size in relation
to the total population were also considerable. These dif-
ferences raise the concern, particularly in the French
RCT, that the characteristics of the enrolled population
contributed to outcomes that differed in degree and
direction from those of the other RCTs.
Management protocols in labor
Fetal scalp blood sampling (FBS) for determination of pH
was optional in all five RCTs but only the Plymouth and
Dutch RCTs had guidelines for this (Table 3). The inter-
pretation algorithm was similar in all five RCTs (scalp
blood pH ≥ 7.25, normal; 7.24–7.20, suspicious/pre-acido-
sis, repeat FBS; <7.20, abnormal/acidosis, deliver or reveal
cause of hypoxia; in the Finnish RCT a pH <7.20 was an
indication of immediate delivery). The Plymouth RCT
used an earlier version of the STAN monitor, the S8801
model, and a CTG+ST interpretation algorithm that dif-
fered from the other RCTs (Table 3). The T/QRS ratio
and ST interval changes were read manually, where a T/
QRS ratio above a certain cut-off or a rapidly emerging
change in the ST interval waveform was regarded as signif-
icant and warranted action (12,24). This situation may
have reduced the reliability of the ST analysis when com-
pared with the automated analysis used in the later RCTs.
Intrapartum interventions: FBS and operative
delivery
The use of FBS ranged from 9.4 to 62% in the CTG-only
groups (Table 4). FBS was reduced in the CTG+ST arm
in all RCTs, but the reduction was only significant in
those with the highest use of FBS, i.e. the Finnish, French
and Dutch RCTs. The total rates of ODFD were reduced
in the CTG+ST arm in all RCTs except the Dutch study,
but the reductions were only significant in the Plymouth
and Swedish RCTs (Table 4). Overall, the total operative
delivery rate, including cesarean sections and instrumental
vaginal deliveries, was significantly reduced only in the
Swedish RCT.
Metabolic acidosis as an outcome parameter
Umbilical cord blood acid–base status at birth was an
outcome parameter in all five RCTs (Table 5). Paired
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cord blood samples from artery and vein were used, but
validation of arterial blood samples was only performed
in the Swedish (revised data report), French and Dutch
RCTs. However, the validation criteria were not uniform
(Table 3). Base deficit (BD) was calculated in the extra-
cellular fluid (BDecf) from measured values of pH and
PCO2 in all trials except the Finnish RCT, in which BD
was calculated in blood (BDblood). Hence, the incidence
of metabolic acidosis in the Finnish RCT cannot be com-
pared directly with that of the other RCTs, because, when
calculated in blood, BD is considerably higher and
metabolic acidosis subsequently more prevalent than
when calculated in extracellular fluid (25,26).
Metabolic acidosis was defined as an umbilical cord
artery blood pH < 7.05 in combination with a
BDecf > 12.0 mmol/L in all but the Finnish RCT. Using
the pH and PCO2 values obtained from blood gas
analyzers, BDecf can be calculated post hoc with the algo-
rithm (in SI units): BDecf = 0.9149 9 (0.23 9 PCO2 9
10[pH6.1]  24.1 + 16.21 9 [pH  7.4]) (25). This
algorithm was originally derived from the work by Sigg-
aard-Andersen (27,28). The Finnish RCT used a Chiron
Diagnostics 348 blood gas analyzer to calculate BDblood.
By recalculating the Finnish RCT data with the BDecf
algorithm, the originally reported metabolic acidosis rates
of 1.7% (12/714) in the CTG+ST analysis group and
0.7% (5/722) in the CTG-only group declined to 0.8%
(6/714) and 0.6% (4/722), respectively [K. Ojala, personal
communication to Welin et al. (7)]. The distinction
between BD calculated in blood and that calculated in
extracellular fluid is important for the diagnosis of meta-
bolic acidosis, since the incidence of BD > 12.0 mmol/L
might differ by a factor of 4 when using different BD
algorithms (26). Hence, for a correct comparison of BD
values and metabolic acidosis rates, the same BD algo-
rithm must be used in comparative studies and MAs.
In the perinatal period, BDecf should be used rather
than BDblood for determining metabolic acidosis, because
the fetus/newborn has a relative increase in the size of the
extracellular fluid compartment compared with that of
the intravascular compartment (29–31). This makes BDecf
more stable and less susceptible to momentary perturba-
tions. The impact of different BD calculations was dem-
onstrated in the Dutch RCT (19), showing a significant
reduction in metabolic acidosis rate in the CTG+ST
group with the BDblood algorithm [risk ratio (RR) 0.63,
95% CI 0.42–0.94] but not with the BDecf algorithm (RR
0.70, 95% CI 0.38–1.28). With BDblood the metabolic aci-
dosis rates were 1.6 and 2.6%, and with BDecf they were
0.7 and 1.1%.
Neonatal outcome: metabolic acidosis, neonatal
intensive care admissions
The proportion of missing cord blood gas data was avail-
able only in the Swedish (7.4%) and Finnish (2.4%) pub-
lications (Table 5), but the Dutch authors reported an
estimated incidence of 20% missing values (16). Imputed
data were calculated in the Dutch RCT and in the revised
version of the Swedish RCT. It can be inferred from the
thesis of Westgate (24) that cases with missing cord blood
gas data were excluded from the analyses of neonatal
variables, and possibly also of other variables in the Plym-
outh RCT. Thirty-six cases (2.4%) with missing blood gas
data were excluded from analyses of neonatal outcome
variables in the Finnish RCT [comparative data retrieved
from Becker et al. (1)] and apparently cases with missing
cord blood data were excluded from the ITT analyses in
the French RCT.
Westgate et al. (12) presented the results of the Plym-
outh RCT as the OR of CTG alone vs. CTG+ST. For com-
parison with the other RCT results we recalculated these
Table 3. Management protocols in labor, umbilical cord blood acid-base characteristics.
Trial Plymouth RCT Swedish RCT Finnish RCT French RCT Dutch RCT
Fetal scalp blood
sampling
Guidelines related to the
CTG in both groups
Optional Optional Optional Guidelines in ST group,
optional in CTG group
ST analysis interpretation
algorithm
Fixed T/QRS ratio cut-offs
(>0.24 > 30 min;
>0.5 > 15 min), ST
changes >5 min
Progressive T/QRS
ratio increases, ST
changes
Progressive T/QRS
ratio increases, ST
changes
Progressive T/QRS
ratio increases, ST
changes
Progressive T/QRS
ratio increases, ST
changes
Cord blood samples Artery + vein Artery + vein Artery + vein Artery + vein Artery + vein
Validation of cord
blood samplesa
No V-A pH ≥ 0.3, A-V
PCO2 ≥ 1.0 kPa
(revised article)
No A-V PCO2 > 0.5 kPa V-A pH ≥ 0.3
Base deficit algorithm
compartment
Extracellular fluid Extracellular fluid Blood Extracellular fluid Extracellular fluid and
blood
CTG, cardiotocography; RCT, randomized controlled trials.
aV, umbilical cord vein; A, umbilical cord artery; V-A, venous-to-arterial difference; A-V, arterial-to-venous difference.
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figures to RR of CTG+ST vs. CTG alone (Table 5). Follow-
ing RR calculation there was a 62% reduction in metabolic
acidosis in the CTG+ST group, but the study was under-
powered to demonstrate a significant difference in this
outcome. Nonsignificant differences were also found for
pH < 7.15, pH < 7.05, Apgar score <7 at 5 min, and
admissions to the neonatal intensive care unit (NICU).
In a re-examination of the original data from the
Swedish database (17), neonates with single vessel cord
blood acid–base values, those with missing cord blood
data but with neonatal blood gases and/or lactate indicat-
ing an affected acid–base status during the first hour of
life, and imputed data in the group with missing data
were included in the ITT analysis of metabolic acidosis.
The revised Swedish RCT is the only study that report
standardized ITT analyses as it included all randomized
cases, irrespective of eligibility and availability of cord
blood gas data. The significant difference in rates of met-
abolic acidosis between the CTG+ST and CTG-only
groups remained (the original figures of 0.69% vs. 1.49%
were recalculated to 0.66% vs. 1.33%). The original RCT
(13) showed an RR for metabolic acidosis of 0.47 with
95% CI 0.25–0.86 (p = 0.015). After correction for mis-
classified cases, the RR for metabolic acidosis was 0.48
with 95% CI 0.24–0.96 (p = 0.038) while the standardized
ITT yielded an RR for metabolic acidosis of 0.50 with
95% CI 0.28–0.88 (p = 0.019) (17).
As mentioned, the Finnish RCT used a different equa-
tion to calculate BD. After communication with the prin-
cipal author, Welin et al. (7) reported the incidence of
metabolic acidosis when the original BDblood was recalcu-
lated to BDecf, showing a reduction from 12 to 6 among
the 714 cases in the CTG+ST group and from 5 to 4
among the 722 cases in the CTG-alone group. Using the
same BDecf algorithm as in the other RCTs, the total
number of cases with metabolic acidosis was reduced
from 17 to 10. The RR (95% CI) for metabolic acidosis
in the CTG+ST arm of 2.43 (0.86–6.85) was reduced to
1.52 (0.43–5.35) (Table 5). This does not alter the origi-
nal conclusion that there was no significant difference
between the groups, but it reduces the differences
between the results of the Finnish RCT and those from
Plymouth, Sweden and the Netherlands. This recalcula-
tion also reduces the reported heterogeneity in the inci-
dence of metabolic acidosis.
In the French RCT, Vayssiere et al. (15) reported a total
of seven cases of BDecf > 12.0 mmol/L with validated
blood samples in the CTG+ST group (7/399, 1.75%) but
presented eight cases of metabolic acidosis (8/399, 2.0%),
defined as pH < 7.05 and BDecf > 12.0 mmol/L. This
divergence remains unexplained. Moreover, the higher
metabolic acidosis rate in the CTG+ST group com-
pared with the CTG-alone group (2.0% vs. 1.25%) isTa
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contradicted by the trend towards a lower rate of
BDecf > 12.0 mmol/L in this arm (1.75% vs. 3.0%, Fishers
exact test p = 0.098). Among cases with validated
cord blood samples there were 19 cases with
BDecf > 12.0 mmol/L, but crude data retrieved from the
individual participant data MA by Schuit et al. (5) showed
a total of 123 cases with a BDecf > 12.0 mmol/L in the
French RCT. These figures indicate that the cord blood
gas samples must have been of inferior quality, because
only 15.4% (19/123) of the samples with BDecf > 12.0 ful-
filled the validation criterion that the cord artery-to-vein
PCO2 difference should be >0.5 kPa. Furthermore, abnor-
mally high BDecf values were reported in 15.4% (123/799)
of cases, compared to 2–4% in the other RCTs. The strik-
ing differences in the composition of the French popula-
tion sample might have limited the ability of the ST
analysis to prevent metabolic acidosis, as also pointed out
by Schuit et al. (5). After quality control, revised data
from the Dutch RCT concerning metabolic acidosis were
published in 2011 (18,19). The number of cases with met-
abolic acidosis was corrected from 50 to 46, but the origi-
nal RR of 0.70 (95% CI 0.38–1.28) remained unchanged
in the CTG+ST arm (16,19).
Admissions to the NICU were reported in all five
RCTs (Table 5). Reductions in NICU admissions by 9–
23% in the CTG+ST groups were reported in four RCTs
and an increase by 1% in one RCT; none of these dif-
ferences were statistically significant. Neonatal encepha-
lopathy and/or seizures were reported in all trials except
in the Plymouth RCT; no significant differences were
found except for encephalopathy stage 1–3, which was
significantly less common in the CTG+ST group in the
Swedish RCT. However, neonatal encephalopathy was
not uniformly defined; only the Swedish and Dutch
RCTs defined this outcome according to Sarnat & Sar-
nat criteria stage 1–3 (32). The Swedish RCT reported
on stage ≥1 and stage ≥2 separately, while the Dutch
RCT reported only on stage ≥2. Westgate provided more
details on neonatal outcome in the Plymouth RCT in
her thesis (24), but they do not allow for the retrospec-
tive classification of neonatal encephalopathy. The Finn-
ish RCT reported more cases of neonatal seizures than
cases with a diagnosis of encephalopathy, which could
be in conflict with the Sarnat & Sarnat definition where
seizure is defined as stage 2 encephalopathy. The French
RCT did not report encephalopathy. Therefore, the
impact of CTG+ST analysis on neonatal encephalopathy
cannot be adequately determined for all cases included
in the trials.
Perinatal mortality was reported in all RCTs except for
the Plymouth study. Data retrieved from the thesis by
Westgate (24) reveal two perinatal deaths in the CTG+ST
group and none in the CTG-alone group. No RCT
showed a significant difference in perinatal mortality
between the study and control groups (Table 5), but all
studies were underpowered to evaluate this outcome.
Summary of major strengths and
weaknesses
Plymouth trial
This initial RCT of the CTG+ST methodology introduced
the essential criteria for intervention used in the subsequent
trials. The trial used an older ST analysis methodology than
the other trials, and supports the hypothesis that ST analy-
sis reduces metabolic acidosis and operative delivery.
Strengths.
• Single-center RCT, suggesting lower risk of inconsis-
tent management
• Power calculation related to metabolic acidosis and
ODFD
• Well-defined inclusion criteria, strict FBS guidelines
related to the CTG pattern
• Interim analysis
• Short study period, high recruitment pace, large trial
Weaknesses.
• Underpowered to evaluate metabolic acidosis, recruit-
ment goal not achieved
• Recruitments started from 34 weeks of gestation
• Not standardized ITT analysis, missing data and exclu-
sions not clear
• Neonatal encephalopathy, seizures, deaths not reported
Swedish trial
The original trial was criticized for the exclusion from the
ITT analysis of randomized cases that did not fulfill the
inclusion criteria. This was addressed in a revised and
standardized ITT analysis, i.e. inclusion of all randomized
cases irrespective of eligibility.
Strengths.
• Power calculation related to metabolic acidosis
• STAN S21 monitors in both trial arms, only internal
monitoring
• Short trial period, high recruitment pace, large trial
• Interim analysis
• Revised article published with single vessel, neonatal
and imputed cord blood gas data included, standardized
ITT analysis addressing metabolic acidosis
• The only trial exposed to external review of crude data
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Weaknesses.
• No clear guidelines for FBS use
• Errors in number of metabolic acidosis in original article
Finnish trial
This is a small trial, aimed to show differences in the
incidence of severe fetal acidemia instead of metabolic
acidosis. When metabolic acidosis was calculated, a differ-
ent BD algorithm was used.
Strengths.
• Single-center RCT, suggesting lower risk of inconsis-
tent management
• Short trial period, high recruitment pace
Weaknesses.
• Primarily not aimed to show metabolic acidosis differ-
ence
• Recruitment goal not achieved for primary outcome
variable “cord artery pH < 7.10”
• Inclusion criterion, “amniotomy,” provides no infor-
mation on fetal risk
• No clear guidelines for FBS use
• Internal or external FHR monitoring in CTG group
• Not standardized ITT, missing data and exclusions not
clear
• BD and metabolic acidosis calculated using a different
algorithm from the other RCTs
French trial
The eligibility criteria of this trial allowed inclusion of
cases with a CTG pattern that indicated fetal hypoxia
before the CTG+ST monitoring was started, violating the
ST analysis clinical guidelines and different from the
other trials. It may be questioned if this trial should be
pooled together with the other trials in comparisons.
Strength.
• Confirmed that ST analysis had no benefit in addition
to conventional CTG in labors with pre-existing evidence
of fetal compromise
Weaknesses.
• Underpowered for evaluation of metabolic acidosis
• Inclusion criterion “abnormal CTG” was a violation of
clinical guidelines for use of CTG+ST monitoring
• Long trial period, low recruitment pace, small trial
• Not standardized ITT, missing data and exclusions not
clear
• No clear guidelines for FBS use
• Internal or external monitoring in CTG group not
specified
• Poor quality of umbilical cord blood samples, unreli-
able blood gas data
Dutch trial
The main weakness of the Dutch RCT is its low recruit-
ment pace. This may have influenced the learning curve
and the results of the trial, but the impact cannot be
determined.
Strengths.
• Power calculation related to metabolic acidosis
• Safety committee watch of serious adverse events
• Well-defined inclusion criteria
• Strict guidelines for FBS use related to CTG+ST pat-
tern (but not to CTG pattern alone)
• Internal electronic monitoring in CTG-alone group
• Largest RCT
• Not completely standardized ITT but only 14 cases
(0.25%) excluded from ITT
• Revised data article published with corrected and
imputed cord blood gas data
Weaknesses.
• Underpowered for metabolic acidosis, recruitment goal
not achieved
• Long trial period, low recruitment pace, many centers
involved
• Errors in number of metabolic acidosis in original article
Conclusions
The perfect RCT to evaluate the CTG+ST methodology
remains to be performed, though “perfect” is probably an
unachievable goal. While the larger Plymouth, Swedish
and Dutch RCTs point towards reduced metabolic acido-
sis rates and reduced operative interventions in the
CTG+ST arm, the smaller Finnish and French RCTs point
towards higher metabolic acidosis rates and minor differ-
ences in operative delivery rates. Because the Finnish RCT
calculated BD in blood rather than in extracellular fluid,
this led to a falsely elevated rate of metabolic acidosis in
comparison with the other RCTs. An adjusted analysis
points to a less divergent result. The French RCT uses an
inclusion criterion - abnormal CTG - which is in conflict
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with the premise for the use of CTG+ST, as ST events
may not appear de novo when fetal hypoxia is already
present. Moreover, the quality of cord blood samples
used in the study is low.
All RCTs, except for the Swedish one, were underpow-
ered for the primary outcome of metabolic acidosis; only
the Plymouth RCT was adequately powered for the pri-
mary outcome of ODFD. The inclusion criteria varied
considerably among the trials, rendering any comparison
of the primary outcomes problematic with such widely
varying a priori risk factors. This finding alone could
explain some of the differences.
Finally, the conduct of the RCTs, including recruitment
pace and total enrollment, interim analysis, and account-
ing for ITT, reflect the difficulties inherent in the under-
taking of large clinical trials. These variations contribute
to the drawbacks of any subsequent MAs, as they will
enhance heterogeneity effects. This is addressed further in
a separate appraisal of the previously published MAs (33).
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Reviewer comments:
The subject under study, fetal surveillance in labor, is definitely of utmost importance. The authors argue in a “sum-
mary of major strengths and weaknesses” that a single-center randomized controlled trial has to be seen as a strength.
I do not agree. Neither do I see that the use of STAN monitors in both trial arms has to be a strength. Why is “No
clear guidelines for fetal scalp blood sampling use” to be seen as a weakness? The major weakness for all studies
seems to be nonadherence to intention-to-treat analyses.
Ove Axelsson
Department of Obstetrics and Gynecology, Uppsala University, Uppsala, Sweden
Reviewer comments:
The authors critically appraised the five randomized controlled trials comparing cardiotocography plus ECG ST inter-
val analysis (CTG+ST) vs. CTG in fetal surveillance during labor published so far. This is an important message since
differences in outcomes between the studies are likely to be explained by significant differences in study designs indi-
cating heterogeneity. It is striking that only five such randomized controlled trials have been reported since 1993.
In conclusion, the authors argue that a proper randomized controlled trial needs to be done. They should take this
one step further, i.e. how to design a proper randomized controlled trial. Inclusion criteria? Power calculation? End
points? For instance, “neonatal intensive care unit” has a totally different meaning in different institutions, and crite-
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